Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.
Comprehensive immunological evaluation is crucial for monitoring patients undergoing antigen-specific cancer immunotherapy. The identification and quantification of T cell responses is most important for the further development of such therapies. Using well-characterized clinical samples from a high...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4546392?pdf=render |
| _version_ | 1818243671817977856 |
|---|---|
| author | Manami Miyai Shingo Eikawa Akihiro Hosoi Tamaki Iino Hirokazu Matsushita Midori Isobe Akiko Uenaka Heiichiro Udono Jun Nakajima Eiichi Nakayama Kazuhiro Kakimi |
| author_facet | Manami Miyai Shingo Eikawa Akihiro Hosoi Tamaki Iino Hirokazu Matsushita Midori Isobe Akiko Uenaka Heiichiro Udono Jun Nakajima Eiichi Nakayama Kazuhiro Kakimi |
| author_sort | Manami Miyai |
| collection | DOAJ |
| description | Comprehensive immunological evaluation is crucial for monitoring patients undergoing antigen-specific cancer immunotherapy. The identification and quantification of T cell responses is most important for the further development of such therapies. Using well-characterized clinical samples from a high responder patient (TK-f01) in an NY-ESO-1f peptide vaccine study, we performed high-throughput T cell receptor β-chain (TCRB) gene next generation sequencing (NGS) to monitor the frequency of NY-ESO-1-specific CD8+ T cells. We compared these results with those of conventional immunological assays, such as IFN-γ capture, tetramer binding and limiting dilution clonality assays. We sequenced human TCRB complementarity-determining region 3 (CDR3) rearrangements of two NY-ESO-1f-specific CD8+ T cell clones, 6-8L and 2F6, as well as PBMCs over the course of peptide vaccination. Clone 6-8L possessed the TCRB CDR3 gene TCRBV11-03*01 and BJ02-01*01 with amino acid sequence CASSLRGNEQFF, whereas 2F6 possessed TCRBV05-08*01 and BJ02-04*01 (CASSLVGTNIQYF). Using these two sequences as models, we evaluated the frequency of NY-ESO-1-specific CD8+ T cells in PBMCs ex vivo. The 6-8L CDR3 sequence was the second most frequent in PBMC and was present at high frequency (0.7133%) even prior to vaccination, and sustained over the course of vaccination. Despite a marked expansion of NY-ESO-1-specific CD8+ T cells detected from the first through 6th vaccination by tetramer staining and IFN-γ capture assays, as evaluated by CDR3 sequencing the frequency did not increase with increasing rounds of peptide vaccination. By clonal analysis using 12 day in vitro stimulation, the frequency of B*52:01-restricted NY-ESO-1f peptide-specific CD8+ T cells in PBMCs was estimated as only 0.0023%, far below the 0.7133% by NGS sequencing. Thus, assays requiring in vitro stimulation might be underestimating the frequency of clones with lower proliferation potential. High-throughput TCRB sequencing using NGS can potentially better estimate the actual frequency of antigen-specific T cells and thus provide more accurate patient monitoring. |
| first_indexed | 2024-12-12T14:04:50Z |
| format | Article |
| id | doaj.art-1d14a6c099144bb680526641484666ee |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-12T14:04:50Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-1d14a6c099144bb680526641484666ee2022-12-22T00:22:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e013608610.1371/journal.pone.0136086Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.Manami MiyaiShingo EikawaAkihiro HosoiTamaki IinoHirokazu MatsushitaMidori IsobeAkiko UenakaHeiichiro UdonoJun NakajimaEiichi NakayamaKazuhiro KakimiComprehensive immunological evaluation is crucial for monitoring patients undergoing antigen-specific cancer immunotherapy. The identification and quantification of T cell responses is most important for the further development of such therapies. Using well-characterized clinical samples from a high responder patient (TK-f01) in an NY-ESO-1f peptide vaccine study, we performed high-throughput T cell receptor β-chain (TCRB) gene next generation sequencing (NGS) to monitor the frequency of NY-ESO-1-specific CD8+ T cells. We compared these results with those of conventional immunological assays, such as IFN-γ capture, tetramer binding and limiting dilution clonality assays. We sequenced human TCRB complementarity-determining region 3 (CDR3) rearrangements of two NY-ESO-1f-specific CD8+ T cell clones, 6-8L and 2F6, as well as PBMCs over the course of peptide vaccination. Clone 6-8L possessed the TCRB CDR3 gene TCRBV11-03*01 and BJ02-01*01 with amino acid sequence CASSLRGNEQFF, whereas 2F6 possessed TCRBV05-08*01 and BJ02-04*01 (CASSLVGTNIQYF). Using these two sequences as models, we evaluated the frequency of NY-ESO-1-specific CD8+ T cells in PBMCs ex vivo. The 6-8L CDR3 sequence was the second most frequent in PBMC and was present at high frequency (0.7133%) even prior to vaccination, and sustained over the course of vaccination. Despite a marked expansion of NY-ESO-1-specific CD8+ T cells detected from the first through 6th vaccination by tetramer staining and IFN-γ capture assays, as evaluated by CDR3 sequencing the frequency did not increase with increasing rounds of peptide vaccination. By clonal analysis using 12 day in vitro stimulation, the frequency of B*52:01-restricted NY-ESO-1f peptide-specific CD8+ T cells in PBMCs was estimated as only 0.0023%, far below the 0.7133% by NGS sequencing. Thus, assays requiring in vitro stimulation might be underestimating the frequency of clones with lower proliferation potential. High-throughput TCRB sequencing using NGS can potentially better estimate the actual frequency of antigen-specific T cells and thus provide more accurate patient monitoring.http://europepmc.org/articles/PMC4546392?pdf=render |
| spellingShingle | Manami Miyai Shingo Eikawa Akihiro Hosoi Tamaki Iino Hirokazu Matsushita Midori Isobe Akiko Uenaka Heiichiro Udono Jun Nakajima Eiichi Nakayama Kazuhiro Kakimi Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient. PLoS ONE |
| title | Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient. |
| title_full | Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient. |
| title_fullStr | Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient. |
| title_full_unstemmed | Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient. |
| title_short | Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient. |
| title_sort | detection and tracking of ny eso 1 specific cd8 t cells by high throughput t cell receptor β tcrb gene rearrangements sequencing in a peptide vaccinated patient |
| url | http://europepmc.org/articles/PMC4546392?pdf=render |
| work_keys_str_mv | AT manamimiyai detectionandtrackingofnyeso1specificcd8tcellsbyhighthroughputtcellreceptorbtcrbgenerearrangementssequencinginapeptidevaccinatedpatient AT shingoeikawa detectionandtrackingofnyeso1specificcd8tcellsbyhighthroughputtcellreceptorbtcrbgenerearrangementssequencinginapeptidevaccinatedpatient AT akihirohosoi detectionandtrackingofnyeso1specificcd8tcellsbyhighthroughputtcellreceptorbtcrbgenerearrangementssequencinginapeptidevaccinatedpatient AT tamakiiino detectionandtrackingofnyeso1specificcd8tcellsbyhighthroughputtcellreceptorbtcrbgenerearrangementssequencinginapeptidevaccinatedpatient AT hirokazumatsushita detectionandtrackingofnyeso1specificcd8tcellsbyhighthroughputtcellreceptorbtcrbgenerearrangementssequencinginapeptidevaccinatedpatient AT midoriisobe detectionandtrackingofnyeso1specificcd8tcellsbyhighthroughputtcellreceptorbtcrbgenerearrangementssequencinginapeptidevaccinatedpatient AT akikouenaka detectionandtrackingofnyeso1specificcd8tcellsbyhighthroughputtcellreceptorbtcrbgenerearrangementssequencinginapeptidevaccinatedpatient AT heiichiroudono detectionandtrackingofnyeso1specificcd8tcellsbyhighthroughputtcellreceptorbtcrbgenerearrangementssequencinginapeptidevaccinatedpatient AT junnakajima detectionandtrackingofnyeso1specificcd8tcellsbyhighthroughputtcellreceptorbtcrbgenerearrangementssequencinginapeptidevaccinatedpatient AT eiichinakayama detectionandtrackingofnyeso1specificcd8tcellsbyhighthroughputtcellreceptorbtcrbgenerearrangementssequencinginapeptidevaccinatedpatient AT kazuhirokakimi detectionandtrackingofnyeso1specificcd8tcellsbyhighthroughputtcellreceptorbtcrbgenerearrangementssequencinginapeptidevaccinatedpatient |